IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1253
Positioning
Market Dominance
Manufacturing
Medical Equipment
$3.0B
Vivek Jain
ICU Medical, Inc. develops, manufactures, and sells medical devices used in infusion therapy and critical care applications. The company's infusion therapy products include needlefree products; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = ICUI ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ICUI ICU MEDICAL INC/DE | 55 | 51 | 67 | 52 | 5052.3x | 85.3x | -0.8% | -0.4% | 36.2% | 2.0% | -0.6% | -10.0% | 0.0% | 91.0x | $3.0B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
ICU MEDICAL INC/DE (ICUI) receives a "Hold" rating with a composite score of 55.1/100. It ranks #1253 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Trading at a discount to fundamentals — favorable entry valuation
Average quality profile
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for ICUI.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 51 | 46 | +5NEUTRAL |
| MOMENTUM | 52 | 47 | +5NEUTRAL |
| VALUATION | 67 | 66 | +1NEUTRAL |
| INVESTMENT | 33 | 52 | -19DRAG |
| STABILITY | 73 | 75 | -2NEUTRAL |
| SHORT INT | 45 | 41 | +4NEUTRAL |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC 3.3% vs WACC 8.7% (spread -5.4%)
GM 36% vs sector 44%, OM 2% vs sector 3%
Capital turnover 2.20x, R&D intensity 3.9%
Rev growth -10%, 10yr history
Interest coverage 0.5x, Net debt/EBITDA 23.7x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate ICU MEDICAL INC/DE (ICUI) as a Hold with a composite score of 55.1/100 at a current price of $152.65. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
ICU MEDICAL INC/DE holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 55.1/100 places it at rank #1253 in our full universe.
No Moat
High
Poor
Undervalued
Value factor score of 67 suggests attractive pricing.
Stable competitive position in a defensive sector.
Elevated P/E ratio of 5052.3x leaves little room for execution misses.
Vulnerability to macroeconomic shocks and interest rate volatility.
ICU MEDICAL INC/DE represents a hold based on multi-factor quantitative performance.
Our model assigns ICU MEDICAL INC/DE a Hold rating, with a composite score of 55.1/100 and 3 out of 5 stars. Ranked #1253 of 7,333 stocks, ICUI presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
With a quality score of 51/100, ICUI shows adequate but unremarkable business quality. The company reports a return on equity of -0.8% (sector avg: -1.9%), gross margins of 36.2% (sector avg: 44.1%), net margins of -0.6% (sector avg: 1.0%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
ICUI's value score of 67/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 5052.33x, an EV/EBITDA of 85.33x, a P/B ratio of 1.83x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
ICU MEDICAL INC/DE's investment score of 33/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -10.0% vs. a sector average of 6.7% and a return on assets of -0.4% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
ICUI demonstrates moderate momentum with a score of 52/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at -10.0% year-over-year, while a beta of 0.98 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
ICUI shows good financial stability with a score of 73/100. Key stability metrics include a beta of 0.98 and a debt-to-equity ratio of 91.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
The short interest score of 45/100 for ICUI suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 91.00x). With a $3.0B market cap (mid-cap), ICU MEDICAL INC/DE may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
ICU MEDICAL INC/DE is a mid-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1253 of 7,333 overall (83rd percentile). Key comparisons include ROE of -0.8% exceeding the -1.9% sector median and operating margins of 2.0% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While ICUI currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Investment (33) is the limiting factor — improvement here would lift the composite score most.
EV/EBITDA 645% ABOVE SECTOR MEDIAN
ROE 59% BELOW SECTOR MEDIAN
Gross Margin 18% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Operator: Good day, and welcome to the ICU Medical, Inc. Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note, today
ICU Medical (Nasdaq:ICUI) shares dipped slightly today on fourth-quarter results that were mixed compared to the consensus forecast.
ICU Medical (ICUI) Q4 2025 earnings call recap: Q4 results, 2026 revenue/EPS guidance, margins, tariffs, and integration progress.
SAN CLEMENTE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the following investor conferences: Raymond James 47th Annual Institutional Investors Conference on March 2, 2026 Company management will present at the Raymond James 47th Annual Institutional Investors Conference in Orlando, FL on Monday, March 2, 2026. The presentation will begin at 11:15
ICU Medical (NASDAQ:ICUI) reported fourth-quarter 2025 revenue of $536 million and said it delivered 2% organic growth in the period and 5% organic growth for the full year, as management pointed to record quarters in both its consumables and infusion systems businesses. The company also highlighted